Skip to main content

Free Content Antimalarial efficacy of piperaquine‐based antimalarial combination therapies: facts and uncertainties

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Summary

Piperaquine is a bisquinoline antimalarial drug extensively used as monotherapy in China in the 1980s and subsequently included as one of the components of the artemisinin‐based combination therapies (ACTs) in the 1990s. Among them, dihydroartemisinin–piperaquine (DHA‐PQP) represents a new and extremely promising fixed combination. Several clinical trials have repeatedly shown that DHA‐PQP is a safe and highly efficacious therapy against uncomplicated Plasmodium falciparum and the asexual stages of Plasmodium vivax malaria. Studies conducted with this drug have reported cure rates consistently above 95%, with the only exception being a study carried out in Papua New Guinea which reported a high rate of treatment failures. Although it has been hypothesized that such treatment failures could be related to cross‐resistance mechanisms between piperaquine and other quinolines or to a reduced susceptibility of parasites to artemisinin derivatives, a critical review of the studies published so far seems to exclude both of these possibilities. Overall, there is now sufficient evidence on the safety and efficacy of the DHA‐PQP therapy. Accordingly, the use of this ACT for the treatment of P. falciparum malaria has been recently approved in the EU via a centralized procedure by the European Medicines Agency. Moreover, it is now recommended globally by the World Health Organization as an option for the first‐line treatment of uncomplicated malaria.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Language: English

Document Type: Research Article

Affiliations: 1:  R&D Area, Sigma-tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy 2:  Barcelona Centre for International Health Research, Hospital Clínic, University of Barcelona, Barcelona, Spain

Publication date: 01 December 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more